We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

66 hedge funds and large institutions have $12.3M invested in Galectin Therapeutics in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 16 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

96% more call options, than puts

Call options by funds: $45K | Put options by funds: $23K

10% more funds holding

Funds holding: 60 → 66 (+6)

3.24% less ownership

Funds ownership: 15.22% → 11.98% (-3.2%)

29% less capital invested

Capital invested by funds: $17.4M → $12.3M (-$5.09M)

38% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 16

Holders
66
Holders Change
+6
Holders Change %
+10%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
10
Reduced
16
Closed
3
Calls
$45K
Puts
$23K
Net Calls
+$22K
Net Calls Change
-$21K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$360K
2
6CM
683 Capital Management
New York
+$215K
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$139K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$93.4K
5
Jane Street
Jane Street
New York
+$65.5K

Top Sellers

Rank Fund Capital Flow
1
Osaic Holdings
Osaic Holdings
Arizona
-$3.93M
2
Millennium Management
Millennium Management
New York
-$145K
3
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$108K
4
CCB
Cutter & Co Brokerage
Missouri
-$23.3K
5
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$22.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
26
Traynor Capital Management
Pennsylvania
$57.6K – – –
Jane Street
27
Jane Street
New York
$56.1K +$65.5K +33,769 New
AWM
28
AE Wealth Management
Kansas
$46.4K – – –
Millennium Management
29
Millennium Management
New York
$46.1K -$145K -74,897 -73%
BCMLT
30
Beacon Capital Management LLC (Tennessee)
Tennessee
$45.9K +$21.9K +11,300 +90%
Creative Planning
31
Creative Planning
Kansas
$40.2K +$7.76K +4,000 +20%
BFM
32
Boothbay Fund Management
New York
$39.4K +$46.1K +23,749 New
Bank of New York Mellon
33
Bank of New York Mellon
New York
$38.3K – – –
RGF
34
Retirement Guys Formula
Ohio
$35.7K +$19.4K +10,000 +87%
STA
35
Summit Trail Advisors
New York
$33.2K – – –
VCM
36
Vivaldi Capital Management
Illinois
$32.6K – – –
Wealth Enhancement Advisory Services
37
Wealth Enhancement Advisory Services
Minnesota
$30.9K – – –
Charles Schwab
38
Charles Schwab
California
$28.9K – – –
WS
39
Wedbush Securities
California
$26K – – –
BSW
40
Buckingham Strategic Wealth
Missouri
$22K – – –
DAS
41
Dynamic Advisor Solutions
Arizona
$21.1K – – –
SKK
42
Shepherd Kaplan Krochuk
Massachusetts
$19.9K – – –
IA
43
Inspire Advisors
Idaho
$18.8K +$22K +11,323 New
Mariner
44
Mariner
Kansas
$18.1K – – –
Citigroup
45
Citigroup
New York
$17.7K +$20.7K +10,650 New
SYBT
46
Stock Yards Bank & Trust
Kentucky
$17.4K – – –
IWC
47
Integrated Wealth Concepts
Massachusetts
$16.6K – – –
BTI
48
Blue Trust Inc
Georgia
$13K – – –
Wells Fargo
49
Wells Fargo
California
$12.6K -$882 -455 -6%
TRCT
50
Tower Research Capital (TRC)
New York
$12.2K -$11.8K -6,089 -45%
1
2
3

GALT Hedge Fund Activity: Q4 2023 in Review

66 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2023, worth a combined $12.3M — down 29% from $17.4M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new GALT positions and 3 closed out — a net gain of 6 holders — while 10 added to existing stakes and 16 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $360K. The largest seller was Osaic Holdings, cutting an estimated $3.93M.

  • 66 institutional investors held Galectin Therapeutics (GALT) as of Q4 2023, up from 60 in Q3 2023.
  • Funds reported $12.3M of Galectin Therapeutics stock for Q4 2023, down 29% quarter-over-quarter.
  • 9 funds opened new Galectin Therapeutics positions in Q4 2023 and 3 closed out, a net change of +6 holders.
  • The largest Galectin Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $360K added.
  • The largest Galectin Therapeutics seller in Q4 2023 was Osaic Holdings, an estimated $3.93M sold.

Based on aggregated 13F filings for Q4 2023.